Trials / Completed
CompletedNCT00150774
Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults
A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (≥ 12 Years) and Adults (≤ 65 Years) Suffering From Idiopathic Generalized Epilepsy With Myoclonic Seizures.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 116 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- —
Summary
A double-blind, placebo-controlled study to assess the efficacy of adjunctive treatment with LEV 3000mg/day in reducing myoclonic seizures in adolescents and adults suffering from idiopathic generalised epilepsy and to evaluate the safety of LEV in the same population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam |
Timeline
- Start date
- 2001-11-01
- Primary completion
- 2004-12-01
- Completion
- 2004-12-01
- First posted
- 2005-09-08
- Last updated
- 2013-09-17
Source: ClinicalTrials.gov record NCT00150774. Inclusion in this directory is not an endorsement.